moderna merck - Search News

Merck and Moderna, melanoma

Moderna, Merck breakthrough could usher in wave of cancer vaccines

Merck and Moderna’s success with a personalized cancer vaccine designed to keep melanoma at bay opens a new avenue of treatment that doctors hope will work against many types of tumors.

· 3d

Merck and Moderna say cancer vaccine shows promise in preventing recurrence of melanoma

· 2d

A vaccine for melanoma recurrence? Merck, Moderna say trial promising

· 10h

Investors Thought Moderna Was Left for Dead. Then Came a Cancer Breakthrough.

After years of contending with steep stock drops, cash burn and political headwinds, Moderna delivered the kind of triumph biotech startups rarely enjoy twice.

· 11h

Health Care Up as Moderna Leads Biotech Higher - Health Care Roundup

· 1d

Why Is Merck Stock Still An Undervalued Mega-Cap In Pharma?

· 1d

Moderna’s cancer vaccine clears phase 3; Ultragenyx lands gene therapy nod

Ultragenyx notched its first gene therapy approval Wednesday when the FDA granted accelerated approval to Genglycos, the first approved treatment for glycogen storage disease type Ia, also known as Vo...

thetechedvocate.org · 14h

This mRNA Cancer Therapy Just Delivered Unprecedented Hope for Millions

· 1d

Moderna, Merck develop vaccine that could help fight against melanoma

BioSpace

Moderna stock nearly doubles as Merck-partnered mRNA cancer vaccine meets Phase 3 goal

Melanoma was slower to recur in patients receiving Merck and Moderna's mRNA vaccine with Keytruda, supporting use of the combination in adjuvant treatment. The partners plan to take the data to the FDA.

Moderna Rockets 93%, Merck Jumps 7% as Melanoma Therapy Meets Primary Goal in Phase 3 Trial

A single Phase 3 readout just shook the cancer treatment world, sending one biotech stock to its biggest single-day gain ever and forcing Wall Street to rethink whether personalized mRNA therapies have finally crossed the line from promising to proven.

Medical Marketing & Media

Rx Rundown: Moderna, Merck, LEO Pharma and more

The Food and Drug Administration granted accelerated approval to Zenbexus, or iberdomide, in combination with daratumumab and hyaluronidase-fihj and dexamethasone for certain adults with previously treated multiple myeloma. The drug is made by Bristol Myers Squibb.

BioSpace

Merck’s Moderna-partnered vaccine success clears view of post-Keytruda future

Investors had been pessimistic about the probability of success for the personalized cancer vaccine intismeran autogene, so the Phase 3 win was a welcome surprise.